Immunosuppression due to MACOP-B does not seem to cure the antiphospholipid syndrome.
Stefani
P M
PM
Pietrogrande
F
F
Sartori
R
R
Girolami
A
A
D000328:Adult; D000974:Antibodies, Antinuclear / Q000276:immunology; D000971:Antineoplastic Combined Chemotherapy Protocols; D016736:Antiphospholipid Syndrome / Q000150:complications* / Q000276:immunology*; D001761:Bleomycin / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007165:Immunosuppression Therapy; D002955:Leucovorin / Q000627:therapeutic use; D016393:Lymphoma, B-Cell / Q000150:complications* / Q000188:drug therapy* / Q000276:immunology; D008727:Methotrexate / Q000627:therapeutic use; D011241:Prednisone / Q000627:therapeutic use; D014750:Vincristine / Q000627:therapeutic use
D000974:Antibodies, Antinuclear; D001761:Bleomycin; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D002955:Leucovorin; D011241:Prednisone; D008727:Methotrexate